Xarelto

TABLE OF CONTENTS

5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Xarelto : Stroke prevention in atrial fibrillation (SPAF)
21 Xarelto : Venous thromboembolism (VTE)
33 Xarelto : Chronic heart failure (CHF)
43 Xarelto : Acute coronary syndrome (ACS)

LIST OF FIGURES
14 Figure 1: Xarelto for SPAF – SWOT analysis
15 Figure 2: Datamonitor Healthcare’s drug assessment summary of Xarelto for SPAF
16 Figure 3: Datamonitor Healthcare’s drug assessment summary of Xarelto for SPAF
18 Figure 4: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 5: Xarelto for venous thromboembolism – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of Xarelto for venous thromboembolism
28 Figure 7: Datamonitor Healthcare’s drug assessment summary of Xarelto for venous thromboembolism
30 Figure 8: Xarelto sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017–26
36 Figure 9: Xarelto for chronic heart failure – SWOT analysis
37 Figure 10: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
38 Figure 11: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
40 Figure 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
48 Figure 13: Xarelto for acute coronary syndrome – SWOT analysis
49 Figure 14: Datamonitor Healthcare’s drug assessment summary for Xarelto in acute coronary syndrome
50 Figure 15: Datamonitor Healthcare’s drug assessment summary for Xarelto in acute coronary syndrome

LIST OF TABLES
6 Table 1: Xarelto drug profile
8 Table 2: Xarelto pivotal trial data in SPAF
10 Table 3: Xarelto late-phase trial data in SPAF
13 Table 4: Xarelto ongoing late-phase clinical trial in SPAF
19 Table 5: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017–26
21 Table 6: Xarelto drug profile
23 Table 7: Xarelto pivotal trial data in venous thromboembolism
25 Table 8: Xarelto late-phase trial data in venous thromboembolism
31 Table 9: Xarelto sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017–26
34 Table 10: Xarelto drug profile
35 Table 11: Xarelto Phase III data in chronic heart failure
41 Table 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
44 Table 13: Xarelto drug profile
46 Table 14: Xarelto pivotal trial data in acute coronary syndrome
47 Table 15: Xarelto ongoing late-phase trial in acute coronary syndrome